We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Erba Unveils New H 7100 Advanced Hematology Analyzer

By LabMedica International staff writers
Posted on 05 Feb 2025
Print article
Image: The H 7100 advanced hematology analyzer is designed to redefine hematology analysis (Photo courtesy of ERBA)
Image: The H 7100 advanced hematology analyzer is designed to redefine hematology analysis (Photo courtesy of ERBA)

ERBA Mannheim (Mannheim, Germany) has unveiled the new H 7100 advanced hematology analyzer that is designed to redefine hematology analysis. This state-of-the-art diagnostic instrument promises a paradigm shift in blood analysis capabilities, catering to the complex needs of clinical laboratories and research facilities.

Hematology analyzers are revolutionizing modern clinical labs, delivering crucial insights into blood composition for diagnosing and monitoring various disorders. With technological advancements, these tools now offer enhanced performance, accuracy, and efficiency. The H 7100 is a breakthrough in hematology diagnostics, redefining the field by enabling rapid, reliable insights for clinicians and enhancing diagnostic accuracy and research capabilities. Equipped with fluorescence flow cytometry technology, the H 7100 has a 70-parameter range including Reticulocytes, Immature Platelet Fraction (IPF) and Immature Granulocytes (IG). These are critical for diagnosing, monitoring and treating conditions like anemia, thrombocytopenia, infection, inflammation and myeloid neoplasms. It offers real-time insights of response to allergic leukemia, anemia, bone marrow failure syndromes and hemolytic disorders.

With its advanced algorithms improving clinical decision-making and patient care, the H 7100 redefines the hematology diagnostics space by enabling rapid, reliable insights for clinicians and enhancing diagnostic accuracy and research capabilities in the field. The H7100 sets itself apart with a throughput of 90 tests per hour for CBC+diff and 70 tests per hour for CBC+Diff+retics. Fully automated, it can become a 2X system by adding additional units and samplers. Its Mentzer Index feature helps differentiate between Iron Deficiency Anemia (IDA) and Beta Thalassemia while its Optical Platelet (Plt-O) feature addresses challenges like pseudo-thrombocytopenia in hematological analysis. Optical platelet count reduces the spurious count and is useful in correcting spurious low platelet counts in EDTA-PTCP patients. Cost-effective and minimizing reagent usage, the H7100 is ideal for large and medium-sized labs, corporate hospitals, and B2B labs.

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.